Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets
This article was originally published in PharmAsia News
Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.
You may also be interested in...
As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets
MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio
AstraZeneca plans to broaden its presence across a wide range of developing markets, including small and mid-sized ones, not only to maximize growth but also to smooth out variations in growth rates across countries and regions, top company executives said in a detailed presentation to analysts on March 16
LONDON - To extend its reach in emerging markets, AstraZeneca PLC today said it had signed an agreement with India's Torrent Pharmaceuticals Ltd. for the rights to sell 18 undisclosed generic drugs in nine territories